The analytical challenge begins with the drug’s unusual chemistry. Cefpodoxime proxetil is sold as a racemic mixture of R- and S-epimers arising from an asymmetric carbon in the proxetil side chain, which means any credible assay must resolve two chromatographic peaks, designated CFP-A and CFP-B, rather than one. Earlier methods relied on solid-phase extraction, liquid chromatography coupled to mass spectrometry, or tandem MS platforms that are expensive and often unavailable in academic or resource-limited laboratories. The new work, published in Discover Chemistry, deliberately takes the opposite approach: a conventional HPLC system with ultraviolet detection, a simple liquid-liquid extraction, and a workflow that a modest laboratory can reproduce without specialized instrumentation.

Getting the chemistry to cooperate required careful optimization. The team screened five mobile phase compositions and found that acetonitrile-water mixtures produced fronting peaks, while methanol-buffer systems at neutral pH caused tailing or splitting because the molecule’s carboxylic acid group, with a pKa of roughly 3.2, was partially ionized. The winning formulation, a 20 millimolar phosphate buffer at pH 3.0 mixed with acetonitrile and methanol in a 40:10:50 ratio, suppressed that ionization and delivered symmetric peaks: CFP-A eluting at 7.4 minutes with an asymmetry of 1.22 and over 8,000 theoretical plates, CFP-B at 8.3 minutes, and a resolution of 2.1 between the two epimers. Baseline separation of everything, including the internal standard, was achieved within fifteen minutes.

Sample preparation was optimized with equal rigor. Four extraction solvents were tested, and tert-butyl methyl ether emerged as the clear winner, recovering 62.24 percent of CFP-A and 58.25 percent of CFP-B from spiked plasma, consistent with the drug’s moderate lipophilicity. A 2³ full factorial design explored centrifugation time, plasma volume, and vortex time, and a descriptive Pareto analysis showed vortex time to be the dominant factor. Seven candidate internal standards were evaluated before eplerenone was selected; it extracted efficiently at 88.39 percent recovery, eluted cleanly at 10.8 minutes, and shared just enough structural similarity with the analyte to normalize sample-to-sample variability without risking metabolic cross-reactivity.

Validation followed the US Food and Drug Administration’s 2018 bioanalytical guidance, and the numbers are impressive for a UV-based method. The assay was linear from 200 to 6,400 nanograms per milliliter using weighted 1/X² regression, a model chosen after unweighted fitting showed the concentration-dependent heteroscedasticity typical of bioanalytical data, with correlation coefficients exceeding 0.999. Inter-day accuracy ranged from minus 4.05 to plus 3.15 percent relative error across quality control levels, and precision stayed below 1.8 percent relative standard deviation, far inside the ±15 percent regulatory window. Blank plasma from six independent donors showed interference of less than 6 percent of the lower limit of quantification response, and the analyte proved stable on the bench, through three freeze-thaw cycles, over thirty days at minus 20 degrees Celsius, and for four hours in the autosampler.

Beyond the assay itself, the researchers synthesized cefpodoxime acid by refluxing the prodrug with dilute sodium hydroxide, then confirmed the product’s identity through melting point, thin-layer chromatography, infrared spectroscopy, and proton NMR. The spectral evidence told a clean chemical story: the ester carbonyl stretch at 1762 wavenumbers that dominates the prodrug’s infrared spectrum vanished in the metabolite, replaced by a broad hydroxyl stretch and a carboxylic acid carbonyl, while the NMR spectrum lost the isopropyl signals of the proxetil group entirely. The recrystallized product reached 98.7 percent chromatographic purity, though the modest yield limited how much full co-validation of the metabolite as a quantified analyte the team could complete, a limitation they acknowledge openly.

The kinetic experiments delivered perhaps the most practically useful finding. In 0.1 normal sodium hydroxide at 37 degrees Celsius, cefpodoxime proxetil hydrolyzed with clean first-order kinetics, a rate constant of 0.049 per minute, and a half-life of just 14.0 minutes, with the metabolite peak accounting for 96.5 percent of theoretical yield by ninety minutes. The alkaline conditions were chosen as a forced stress, not to mimic physiology, but the message for any laboratory handling these samples is stark: under basic conditions the prodrug does not survive long. Maintaining appropriate pH during plasma collection and preparation is essential to prevent ex vivo conversion from silently corrupting pharmacokinetic data.

Biological and computational checks rounded out the picture. In broth microdilution assays, the synthesized metabolite inhibited Escherichia coli ATCC 25922 at the same minimum inhibitory concentration as the parent drug, 125 nanograms per milliliter, and came within a single two-fold dilution step against Bacillus subtilis ATCC 6633, a difference the authors correctly attribute to the inherent granularity of the method. TOPKAT in silico toxicity predictions, all performed within the software’s validated optimum prediction space, flagged neither compound as mutagenic, developmentally toxic, or carcinogenic, with only mild ocular irritancy predicted for both. The authors are careful to frame these as preliminary computational screens rather than substitutes for experimental toxicology.

What elevates the study above a routine method validation is its sustainability accounting. Using the AGREE metric, which scores adherence to the twelve principles of green analytical chemistry on a scale from 0 to 1, the method earned 0.65, reflecting a simple workflow held back mainly by the organic solvent consumed in extraction. The White Analytical Chemistry framework, which balances analytical performance, environmental impact, and practical efficiency, returned component scores of 75, 44, and 63 respectively, for an overall score of 61. No previously published cefpodoxime method has reported standardized greenness metrics, making this one of the first cefpodoxime bioanalytical platforms to be graded on environmental terms.

For pharmacokinetic, bioavailability, and bioequivalence studies, the practical implications are considerable. A validated, economical UV-based assay that resolves both epimers and can chromatographically monitor the active metabolite on the same platform gives generic manufacturers and academic laboratories a realistic alternative to mass spectrometry. The authors position the current work as a foundation: once larger quantities of characterized cefpodoxime acid become available, the same chromatographic system could be extended to a fully validated simultaneous parent-metabolite assay. In an era when antibiotic development desperately needs reliable bioanalytical tools, a method that is fast, cheap, regulatorily compliant, and honestly graded for its environmental cost is a quiet but genuine advance.

Subject of Research: Development and validation of an RP-HPLC bioanalytical method for quantifying cefpodoxime proxetil epimers and its active metabolite cefpodoxime acid in human plasma

Article Title: Development and validation of an RP-HPLC method for cefpodoxime proxetil epimers in human plasma with metabolite characterization, hydrolysis kinetics, and sustainability assessment

Article References: Chhajed, S. S., Chikhale, H. U., Sonawane, S. S., & Panja, A. (2026). Development and validation of an RP-HPLC method for cefpodoxime proxetil epimers in human plasma with metabolite characterization, hydrolysis kinetics, and sustainability assessment. Discover Chemistry, 3(1), Article 572. https://doi.org/10.1007/s44371-026-01013-9

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01013-9

Keywords: cefpodoxime proxetil, cefpodoxime acid, RP-HPLC, bioanalytical validation, human plasma, hydrolysis kinetics, prodrug, cephalosporin antibiotics, green analytical chemistry, AGREE metric, White Analytical Chemistry, TOPKAT toxicity prediction

The clinical pairing is a familiar one in oncology wards. Cytarabine, chemically known as cytosine arabinoside or Ara-C, is a pyrimidine nucleoside analogue that leukemia cells take up and phosphorylate into an active triphosphate form. Once converted, it is incorporated into DNA and blocks DNA polymerase, halting the proliferation of the rapidly dividing cells that drive acute myeloid leukemia, the most common acute leukemia in adults. But cytarabine is also classified as an emetogenic agent, meaning it frequently triggers nausea and vomiting, particularly at high doses or in combination regimens. That is where granisetron comes in. As a selective antagonist of the 5-hydroxytryptamine type-3 receptor, it blocks serotonin signaling in both the gastrointestinal tract and the central nervous system, preventing and treating chemotherapy-induced nausea and vomiting in adult and pediatric patients alike.

Because the two drugs travel together in a patient’s bloodstream, measuring them simultaneously in a biological matrix is clinically valuable for therapeutic drug monitoring, pharmacokinetic studies, and bioanalytical applications. Yet, according to the research team led by Salwa I. Tohamy, Eglal A. Abdelaleem, Adel Lashien, Mahmoud M. Amin, and Nessreen S. Abdelhamid, no reverse-phase HPLC method had previously been reported for the simultaneous determination of cytarabine and granisetron in spiked human plasma. Existing options had drawbacks: many published HPLC methods handled only a single analyte or demanded complex sample preparation and long analysis times, while liquid chromatography-tandem mass spectrometry, though exquisitely sensitive, requires expensive instrumentation that is not routinely available in every laboratory.

The new method relies on a Thermo Scientific Dionex Ultimate 3000 HPLC system equipped with a reverse-phase C18 column measuring 25 centimeters long with a 4.6 millimeter internal diameter and 5 micrometer particles. Separation was achieved using gradient elution with a mobile phase composed of water containing 0.1 percent triethylamine, adjusted to pH 6 with orthophosphoric acid, mixed with methanol. Detection was performed at 290 nanometers using a diode array detector. The gradient program completes within 15 minutes, followed by a 3-minute re-equilibration step, giving a total run time of 18 minutes per sample. Getting there required considerable optimization. The team screened ethanol, acetonitrile, and phosphate buffer combinations, and tested isocratic methanol-buffer mixtures at several ratios, but none resolved the two drugs adequately. Gradient systems based on methanol and acetonitrile caused granisetron peak tailing and overlap with the internal standard. The breakthrough came with the addition of 0.1 percent triethylamine, which sharply reduced tailing and improved separation.

Sample preparation is deliberately simple. One milliliter of human plasma is mixed with caffeine, which serves as the internal standard, and diluted with HPLC-grade methanol. The mixture is vortexed for five minutes to precipitate proteins, centrifuged at 4000 rpm for ten minutes, and the clear supernatant is filtered through a 0.22 micrometer syringe filter before a 10 microliter aliquot is injected. Caffeine was chosen after the researchers tested paracetamol, ketoprofen, dapoxetine, and furosemide as alternatives; it offered the right retention time, sharp peak shape, and baseline separation from both drugs, and it is not endogenously present in plasma at interfering levels under the analytical conditions used.

Validation followed the U.S. Food and Drug Administration’s 2018 Bioanalytical Method Validation Guidance, the International Council for Harmonisation M10 guideline from 2022, and relevant principles of ICH Q2(R2). The method proved linear from 0.1 to 20 micrograms per milliliter for cytarabine and 0.3 to 20 micrograms per milliliter for granisetron, in both pure solutions and spiked plasma, with correlation coefficients of 0.9999 across all calibration curves. Accuracy and precision were assessed at five quality control levels, from the lower limit of quantification through the upper limit, and all results fell within the regulatory acceptance limits of plus or minus 15 percent for quality control samples and plus or minus 20 percent at the lower limit. Selectivity testing across six different blank plasma samples showed no interfering peaks at the retention times of either drug or the internal standard.

The researchers also probed how the plasma matrix itself might distort results. Matrix effect values ranged from 92.84 to 102.31 percent for cytarabine and 88.89 to 101.91 percent for granisetron, indicating no significant ion suppression or enhancement and a consistent analytical response across quality control levels. Stability studies confirmed that both drugs survive realistic laboratory handling: samples held at room temperature for six hours, kept in the autosampler for 24 hours, or subjected to three freeze-thaw cycles at minus 20 degrees Celsius all recovered within acceptable limits, with coefficients of variation below 2 percent. Robustness testing, which introduced small deliberate variations in methanol composition, flow rate, and detection wavelength, showed no meaningful impact on performance.

What distinguishes this study from many analytical papers is its self-critical environmental accounting. The team applied three complementary assessment tools. The AGREE metric, which evaluates the twelve principles of green analytical chemistry including energy consumption and waste generation, returned a score of 0.68, above the 0.6 threshold considered acceptable for green analytical methods. The Green Analytical Procedure Index, or GAPI, produced a pictogram with three red, nine yellow, and three green sections, with the predominance of yellow pointing to room for improvement in chemical use efficiency and waste generation. The multicolor assessment framework, which quantifies whiteness in the sense of white analytical chemistry, yielded an overall whiteness score of 68.7 percent, with the reliability component scoring highest at 82.5 percent and the blueness component at 77.5 percent.

Compared with recently reported chromatographic methods for these two drugs, the new approach consumes less solvent, requires less sample preparation, and runs faster, while extending applicability to biological matrices rather than being limited to pharmaceutical dosage forms. A statistical comparison using one-way ANOVA found no significant differences in accuracy or precision relative to the published methods, meaning the greener design did not come at the cost of analytical quality. The authors suggest the method is well suited for routine bioanalytical work and therapeutic drug monitoring in clinical settings, where laboratories may lack mass spectrometry infrastructure but still need reliable, sensitive measurements of these two co-administered drugs.

Beyond its immediate application, the study reflects a broader shift in analytical chemistry, where the environmental footprint of a method is now evaluated as rigorously as its sensitivity and precision. Solvent-heavy chromatography has long been an accepted cost of doing business in pharmaceutical analysis, but frameworks like AGREE, GAPI, and the multicolor assessment give laboratories a standardized vocabulary for demanding better. For leukemia patients, the practical payoff is a faster, cheaper, and cleaner way to ensure that the delicate balance between a life-saving chemotherapy drug and its anti-nausea companion is tracked accurately in the bloodstream, using equipment that most hospital and university laboratories already possess.

Subject of Research: Green gradient RP-HPLC determination of cytarabine and granisetron in spiked human plasma with greenness and whiteness assessment

Article Title: Green gradient RP HPLC for determination of cytarabine and granisetron in spiked human plasma with greenness and whiteness assessment

Article References: Tohamy, S. I., Abdelaleem, E. A., Lashien, A., Amin, M. M., & Abdelhamid, N. S. (2026). Green gradient RP HPLC for determination of cytarabine and granisetron in spiked human plasma with greenness and whiteness assessment. Discover Chemistry, 3(1), Article 559. https://doi.org/10.1007/s44371-026-00983-0

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00983-0

Keywords: cytarabine, granisetron, RP-HPLC, human plasma, acute myeloid leukemia, chemotherapy-induced nausea and vomiting, green analytical chemistry, AGREE metric, GAPI, white analytical chemistry, therapeutic drug monitoring, bioanalytical method validation

The new assay targets three biologically interconnected classes of circulating proteins that together paint a detailed portrait of metabolic health: adipokines, the signaling molecules secreted by fat tissue that regulate appetite, insulin sensitivity, and inflammation; apolipoproteins, the protein scaffolds of lipoprotein particles that govern cholesterol and triglyceride transport; and inflammatory proteins, whose chronic elevation in obesity contributes to tissue damage and metabolic dysfunction. Rather than measuring these proteins one at a time with traditional immunoassays, which can suffer from antibody cross-reactivity and poor standardization across laboratories, the team harnessed targeted mass spectrometry, a technique that identifies and quantifies proteins by detecting characteristic peptide fragments with exquisite molecular specificity. The approach, often described as selected reaction monitoring when performed on triple quadrupole instruments, essentially gives each target protein a unique molecular fingerprint that can be counted with high precision.

Developing a robust assay for 42 proteins at once is no small technical undertaking, and the researchers invested considerable effort in optimization at every step of the workflow. They carefully selected surrogate peptides, short amino acid sequences released when plasma proteins are enzymatically digested, choosing fragments that are unique to each target protein, chemically stable, and reproducibly generated by the digestion enzyme trypsin. Digestion incubation time was systematically tuned to ensure complete and consistent protein breakdown, and the liquid chromatography gradient used to separate peptides before mass analysis was refined to resolve all targets within a single analytical run. The assay was then rigorously evaluated for linearity across a wide concentration range, for its lower limit of quantification, for imprecision between runs, and for the stability of measurements over time, all critical parameters for any assay that might eventually leave the research laboratory and enter clinical use.

A key innovation of the study is the semi-automated sample preparation workflow built around standard 96-well plates, the same format used in high-throughput clinical chemistry laboratories. Plasma samples are subjected to protein denaturation, reduction with dithiothreitol, alkylation with iodoacetamide, and enzymatic digestion, all in a plate-based format that minimizes manual handling and reduces variability between samples. Stable-isotope labeled versions of the surrogate peptides are spiked into each sample as internal standards, allowing the light-to-heavy peak area ratios measured by the mass spectrometer to be converted into absolute protein concentrations. This isotope dilution strategy is one of the hallmarks of targeted mass spectrometry, providing a level of quantitative accuracy and inter-laboratory reproducibility that antibody-based methods have historically struggled to achieve.

To demonstrate that the assay could travel between laboratories, the team conducted an inter-laboratory validation using plasma samples from 70 healthy individuals analyzed according to a finalized standard operating procedure. The results from the two sites showed strong correlation, providing convincing evidence that the assay’s performance is not an artifact of a single instrument or operator but a transferable, standardized measurement. This kind of reproducibility testing is essential if protein biomarkers are ever to be used consistently in multi-center clinical trials or, ultimately, in routine patient care, where results generated in different hospitals must be directly comparable.

With the analytical platform validated, the researchers applied it to a clinical cohort of individuals enrolled in a weight loss intervention study, comparing protein abundance across obese, overweight, and healthy control groups. The multiplexed measurements revealed significant differences in the levels of six proteins across the three groups, and when obese individuals were compared with all non-obese participants combined, sixteen proteins emerged as differentially abundant. These findings underscore the value of measuring many biomarkers in parallel: rather than relying on a single protein signal, the assay captures a coordinated molecular pattern that reflects the systemic physiology of obesity, from altered lipid transport to chronic low-grade inflammation and changes in adipose tissue signaling.

Perhaps the most clinically intriguing result came from tracking biomarker changes over the course of the weight loss intervention. Among participants, the researchers identified four proteins whose plasma concentrations changed significantly in individuals who achieved more than five percent body weight loss: C-reactive protein, a well-known marker of systemic inflammation; proteoglycan 4, or PRG4, a lubricating glycoprotein more famous for its role in joint health; pigment epithelium-derived factor, known as SERPINF1, which has been implicated in metabolic regulation; and sex hormone-binding globulin, or SHBG, a liver-derived protein whose levels typically rise as insulin sensitivity improves. The fact that these molecular shifts were detectable specifically in responders suggests the assay could serve as an objective, quantitative readout of whether a weight loss intervention is genuinely altering a patient’s metabolic biology, not merely the number on a scale.

The implications extend beyond obesity itself. Because the panel includes apolipoproteins and inflammatory markers with established ties to cardiovascular disease and type 2 diabetes, the same assay could support risk stratification studies aimed at identifying which individuals with obesity are most likely to develop downstream complications. It could also accelerate pharmaceutical research, where candidate anti-obesity drugs must be evaluated for their effects on circulating protein biomarkers in early-phase trials. The high-throughput plate-based format means hundreds of samples can be processed efficiently, making the platform well suited to the large longitudinal cohorts that such studies demand, and the open publication of the standard operating procedure lowers the barrier for other laboratories to adopt and extend the method.

It is worth emphasizing what this study does and does not claim. The assay is a research tool today, not a diagnostic test cleared for clinical use, and the biomarker findings in the intervention cohort, while statistically significant, will require confirmation in larger and more diverse populations. Nevertheless, the work represents a meaningful demonstration that targeted mass spectrometry can deliver precise, multiplexed, and reproducible protein measurements from a small volume of plasma, addressing long-standing limitations of antibody-based biomarker assays. As the cost of high-resolution mass spectrometers continues to fall and standardized protocols like this one proliferate, the vision of a molecularly detailed blood test that quantifies dozens of health-relevant proteins in a single run is moving steadily closer to reality, and obesity medicine may be one of the first fields to benefit.

Subject of Research: Multiplexed targeted mass spectrometry quantification of obesity-associated plasma protein biomarkers

Article Title: A multiplexed targeted mass spectrometric assay for quantifying obesity-associated biomarkers in human plasma

Article References: Lin, T.-T., Dakup, P. P., Schepmoes, A. A., Fillmore, T. L., Swensen, A. C., Kelly, S. S., Zhang, T., Pu, J., Jacobs, J. M., DeLany, J. P., Goodpaster, B. H., Shi, T., Qu, J., & Qian, W.-J. (2026). A multiplexed targeted mass spectrometric assay for quantifying obesity-associated biomarkers in human plasma. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09625-0

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09625-0

Keywords: obesity, biomarkers, mass spectrometry, human plasma, adipokines, apolipoproteins, inflammatory proteins, weight loss, proteomics, CRP, SHBG, clinical assay